Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF registry sub-cohort analysis.

Shinya SuzukiTakeshi YamashitaMasaharu AkaoKen Okumuranull null

Published in: European journal of clinical pharmacology (2020)

A high trough apixaban level in patients indicated for standard dose was not associated with adverse events, while a high apixaban level in patients indicated for a reduced dose was associated with bleeding requiring hospitalization.

Keyphrases

atrial fibrillation
end stage renal disease
newly diagnosed
ejection fraction
prognostic factors
heart failure
acute coronary syndrome
patient reported outcomes
coronary artery disease
left ventricular
left atrial
clinical evaluation